L-dopa for Parkinson's (NCT07370532)
Reduce Parkinson progression with antiinflammatory
- Trial ID
- NCT07370532
- Official Title
- Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
- Goal
- Reduce Parkinson progression with antiinflammatory
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Ihab Elsayed Hassan
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson Disease
- Interventions
- L-dopa, Etoricoxib
Summary For Families
Researchers are testing whether adding etoricoxib, a selective COX-2 anti-inflammatory, to usual levodopa care is safe and may help by reducing the inflammation that might contribute to neuron damage and symptom worsening in Parkinson's. Etoricoxib works by blocking the COX-2 enzyme and lowering prostaglandin-driven inflammation; it does not boost dopamine like levodopa, but by reducing inflammatory stress it could protect neurons or slow decline, and the study will watch for safety and interactions with standard Parkinson's drugs. The trial plans to enroll about 60 people aged 50 to 70 with Parkinson's diagnosed using the UPDRS who are on conventional treatment. People who are pregnant or breastfeeding, have significant liver or kidney problems, current use of other anti-inflammatory drugs, substance abuse, or known allergy to the medications are excluded.
Locations
- Mansoura University, Al Mansurah, Egypt
Frequently Asked Questions
- What is this trial testing?
- This trial is studying L-dopa. Researchers are testing whether adding etoricoxib, a selective COX-2 anti-inflammatory, to usual levodopa care is safe and may help by reducing the inflammation that might contribute to neuron damage and symptom worsening in Parkinson's. Etoricoxib works by blocking the COX-2 enzyme and lowering prostaglandin-driven inflammation; it does not boost dopamine like levodopa, but by reducing inflammatory stress it could protect neurons or slow decline, and the study will watch for safety and interactions with standard Parkinson's drugs. The trial plans to enroll about 60 people aged 50 to 70 with Parkinson's diagnosed using the UPDRS who are on conventional treatment. People who are pregnant or breastfeeding, have significant liver or kidney problems, current use of other anti-inflammatory drugs, substance abuse, or known allergy to the medications are excluded.
- Who can participate?
- Participants must be between 50 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 1 year and 9 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.